Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash Reviewing TriActiv Distal Protection Marketing Options

This article was originally published in The Gray Sheet

Executive Summary

Completion of the 50-center, 800-patient, randomized U.S. PRIDE trial of the TriActiv distal protection system in coming months will clear the way for a 510(k) submission by year-end, Kensey Nash says
Advertisement

Related Content

Kensey Nash TriActiv Safety With Small Guiding Catheters Is Equal To Control
Kensey Nash TriActiv Safety With Small Guiding Catheters Is Equal To Control
Embolic Protection Competition Fueled By Next-Generation Devices
Embolic Protection Competition Fueled By Next-Generation Devices
Cyberonics Shares Up 14% In June, Stimulated By Pending D-04 Trial Results
Cyberonics Shares Up 14% In June, Stimulated By Pending D-04 Trial Results
Transcatheter Therapeutics Conference In Brief
Kensey Nash TriActiv
Advertisement
UsernamePublicRestriction

Register

MT018628

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel